Compare Citius Pharmaceuticals Inc (CTXR) vs TeraWulf Inc (WULF) Price & Performance

CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.

Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.

WULF trades at $20.89, down 4.92% on the day, with a bearish technical signal and negative earnings trends. The company reported a net loss of $661.42 million in 2025, with revenue of $168.46 million, but secured a significant 20-year, $19 billion AI infrastructure deal with Anthropic, driving positive analyst sentiment. Key support lies at $20, with resistance at $21.

The outlook hinges on execution of the Anthropic partnership, offering substantial growth potential, but high valuation ratios and persistent losses pose risks. Analyst consensus is strongly bullish with a $35.40 price target, though operational cash flow remains negative. Investors face volatility from execution delays and competitive pressures in AI infrastructure.